Stroke genetics informs drug discovery and risk prediction across ancestries

Previous genome-wide association studies (GWASs) of stroke — the second leading cause of death worldwide — were conducted predominantly in populations of European ancestry1,2. Here, in cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and...

Full description

Bibliographic Details
Main Authors: Mishra, A, Malik, R, Hachiya, T, Lin, K, Chen, Z, Walters, R, Millwood, I, Debette, S
Format: Journal article
Language:English
Published: Springer Nature 2022
_version_ 1826309054565187584
author Mishra, A
Malik, R
Hachiya, T
Lin, K
Chen, Z
Walters, R
Millwood, I
Debette, S
author_facet Mishra, A
Malik, R
Hachiya, T
Lin, K
Chen, Z
Walters, R
Millwood, I
Debette, S
author_sort Mishra, A
collection OXFORD
description Previous genome-wide association studies (GWASs) of stroke — the second leading cause of death worldwide — were conducted predominantly in populations of European ancestry1,2. Here, in cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and 1,503,898 control individuals, we identify association signals for stroke and its subtypes at 89 (61 new) independent loci: 60 in primary inverse-variance-weighted analyses and 29 in secondary meta-regression and multitrait analyses. On the basis of internal cross-ancestry validation and an independent follow-up in 89,084 additional cases of stroke (30% non-European) and 1,013,843 control individuals, 87% of the primary stroke risk loci and 60% of the secondary stroke risk loci were replicated (P < 0.05). Effect sizes were highly correlated across ancestries. Cross-ancestry fine-mapping, in silico mutagenesis analysis3, and transcriptome-wide and proteome-wide association analyses revealed putative causal genes (such as SH3PXD2A and FURIN) and variants (such as at GRK5 and NOS3). Using a three-pronged approach4, we provide genetic evidence for putative drug effects, highlighting F11, KLKB1, PROC, GP1BA, LAMC2 and VCAM1 as possible targets, with drugs already under investigation for stroke for F11 and PROC. A polygenic score integrating cross-ancestry and ancestry-specific stroke GWASs with vascular-risk factor GWASs (integrative polygenic scores) strongly predicted ischaemic stroke in populations of European, East Asian and African ancestry5. Stroke genetic risk scores were predictive of ischaemic stroke independent of clinical risk factors in 52,600 clinical-trial participants with cardiometabolic disease. Our results provide insights to inform biology, reveal potential drug targets and derive genetic risk prediction tools across ancestries.
first_indexed 2024-03-07T07:28:30Z
format Journal article
id oxford-uuid:2df5a30e-a647-4308-9db6-0d959e32183a
institution University of Oxford
language English
last_indexed 2024-03-07T07:28:30Z
publishDate 2022
publisher Springer Nature
record_format dspace
spelling oxford-uuid:2df5a30e-a647-4308-9db6-0d959e32183a2022-12-20T09:30:08ZStroke genetics informs drug discovery and risk prediction across ancestriesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2df5a30e-a647-4308-9db6-0d959e32183aEnglishSymplectic ElementsSpringer Nature2022Mishra, AMalik, RHachiya, TLin, KChen, ZWalters, RMillwood, IDebette, SPrevious genome-wide association studies (GWASs) of stroke — the second leading cause of death worldwide — were conducted predominantly in populations of European ancestry1,2. Here, in cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and 1,503,898 control individuals, we identify association signals for stroke and its subtypes at 89 (61 new) independent loci: 60 in primary inverse-variance-weighted analyses and 29 in secondary meta-regression and multitrait analyses. On the basis of internal cross-ancestry validation and an independent follow-up in 89,084 additional cases of stroke (30% non-European) and 1,013,843 control individuals, 87% of the primary stroke risk loci and 60% of the secondary stroke risk loci were replicated (P < 0.05). Effect sizes were highly correlated across ancestries. Cross-ancestry fine-mapping, in silico mutagenesis analysis3, and transcriptome-wide and proteome-wide association analyses revealed putative causal genes (such as SH3PXD2A and FURIN) and variants (such as at GRK5 and NOS3). Using a three-pronged approach4, we provide genetic evidence for putative drug effects, highlighting F11, KLKB1, PROC, GP1BA, LAMC2 and VCAM1 as possible targets, with drugs already under investigation for stroke for F11 and PROC. A polygenic score integrating cross-ancestry and ancestry-specific stroke GWASs with vascular-risk factor GWASs (integrative polygenic scores) strongly predicted ischaemic stroke in populations of European, East Asian and African ancestry5. Stroke genetic risk scores were predictive of ischaemic stroke independent of clinical risk factors in 52,600 clinical-trial participants with cardiometabolic disease. Our results provide insights to inform biology, reveal potential drug targets and derive genetic risk prediction tools across ancestries.
spellingShingle Mishra, A
Malik, R
Hachiya, T
Lin, K
Chen, Z
Walters, R
Millwood, I
Debette, S
Stroke genetics informs drug discovery and risk prediction across ancestries
title Stroke genetics informs drug discovery and risk prediction across ancestries
title_full Stroke genetics informs drug discovery and risk prediction across ancestries
title_fullStr Stroke genetics informs drug discovery and risk prediction across ancestries
title_full_unstemmed Stroke genetics informs drug discovery and risk prediction across ancestries
title_short Stroke genetics informs drug discovery and risk prediction across ancestries
title_sort stroke genetics informs drug discovery and risk prediction across ancestries
work_keys_str_mv AT mishraa strokegeneticsinformsdrugdiscoveryandriskpredictionacrossancestries
AT malikr strokegeneticsinformsdrugdiscoveryandriskpredictionacrossancestries
AT hachiyat strokegeneticsinformsdrugdiscoveryandriskpredictionacrossancestries
AT link strokegeneticsinformsdrugdiscoveryandriskpredictionacrossancestries
AT chenz strokegeneticsinformsdrugdiscoveryandriskpredictionacrossancestries
AT waltersr strokegeneticsinformsdrugdiscoveryandriskpredictionacrossancestries
AT millwoodi strokegeneticsinformsdrugdiscoveryandriskpredictionacrossancestries
AT debettes strokegeneticsinformsdrugdiscoveryandriskpredictionacrossancestries